語系:
繁體中文
English
說明(常見問題)
回圖書館首頁
手機版館藏查詢
登入
回首頁
切換:
標籤
|
MARC模式
|
ISBD
Cancer drug discovery = science and ...
~
Kim, Kyu-Won.
FindBook
Google Book
Amazon
博客來
Cancer drug discovery = science and history /
紀錄類型:
書目-電子資源 : Monograph/item
正題名/作者:
Cancer drug discovery/ by Kyu-Won Kim ... [et al.].
其他題名:
science and history /
其他作者:
Kim, Kyu-Won.
出版者:
Dordrecht :Springer Netherlands : : 2016.,
面頁冊數:
xvii, 276 p. :ill., digital ;24 cm.
內容註:
Part Ⅰ. A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part Ⅱ. Cancer Drug Discovery - Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1 A historical background of cancer chemotherapy -- 3.2 Development of the anticancer drug screening systems -- 3.3 Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1 Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1 Plant-derived anticancer drugs -- 6.2 Anticancer antibiotics -- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2 Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part Ⅲ. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs.
Contained By:
Springer eBooks
標題:
Antineoplastic agents - Development. -
電子資源:
http://dx.doi.org/10.1007/978-94-024-0844-7
ISBN:
9789402408447
Cancer drug discovery = science and history /
Cancer drug discovery
science and history /[electronic resource] :by Kyu-Won Kim ... [et al.]. - Dordrecht :Springer Netherlands :2016. - xvii, 276 p. :ill., digital ;24 cm.
Part Ⅰ. A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part Ⅱ. Cancer Drug Discovery - Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1 A historical background of cancer chemotherapy -- 3.2 Development of the anticancer drug screening systems -- 3.3 Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1 Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1 Plant-derived anticancer drugs -- 6.2 Anticancer antibiotics -- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2 Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part Ⅲ. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs.
This book describes the history of cancer drugs development to provide insight into the successes and the shortcomings of this enterprise. Most cancer drug treatments target the cancer cell as the core component and as such are very effective in inhibiting their proliferation. However, these cancer drugs are generally ineffective against metastasis, which are tightly linked to the whole body as a system. This book illustrates the problems in cancer drug design and suggests a more systemic view of cancer with a more adapted research approach. The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs, which has been deeply influenced by the 'cell concept' of cancer. Future directions for the development of new anticancer drugs will also be presented. This book has been separated into three sections, providing an overview of: - The scientific progress in the biological sciences over the last 60 years and the influence this progress has had in cancer research. Summaries and charts of important discoveries complete this overview - The process of anticancer drug development with a focus on the characteristic drug groups of each era, illustrated by comprehensive timelines and conceptual cartoons - The limitations of the current cancer drug development pipelines and the new directions for cancer drug discovery, considering a more systemic view of cancer This book is a useful reference for scientists and clinicians working in the biomedical field and for oncologists aiming to explore the landscape of human endeavor in the fight against cancer.
ISBN: 9789402408447
Standard No.: 10.1007/978-94-024-0844-7doiSubjects--Topical Terms:
752563
Antineoplastic agents
--Development.
LC Class. No.: RS431.A64
Dewey Class. No.: 615.798
Cancer drug discovery = science and history /
LDR
:05191nmm a2200313 a 4500
001
2080527
003
DE-He213
005
20161114141448.0
006
m d
007
cr nn 008maaau
008
170616s2016 ne s 0 eng d
020
$a
9789402408447
$q
(electronic bk.)
020
$a
9789402408423
$q
(paper)
024
7
$a
10.1007/978-94-024-0844-7
$2
doi
035
$a
978-94-024-0844-7
040
$a
GP
$c
GP
041
0
$a
eng
050
4
$a
RS431.A64
072
7
$a
MJCL
$2
bicssc
072
7
$a
MED062000
$2
bisacsh
082
0 4
$a
615.798
$2
23
090
$a
RS431.A64
$b
C215 2016
245
0 0
$a
Cancer drug discovery
$h
[electronic resource] :
$b
science and history /
$c
by Kyu-Won Kim ... [et al.].
260
$a
Dordrecht :
$b
Springer Netherlands :
$b
Imprint: Springer,
$c
2016.
300
$a
xvii, 276 p. :
$b
ill., digital ;
$c
24 cm.
505
0
$a
Part Ⅰ. A Scientific Overview on Cancer -- 1. Advancements in Life Sciences and Characteristic Features of Cancer Cells -- 1.1 Characteristics of cancer cells -- 1.2 Characteristic interactions of cancer cells with neighboring cells and the tumor microenvironment -- 2. Advancement of the Science and History of Cancer and Anticancer Drugs -- Part Ⅱ. Cancer Drug Discovery - Types and History -- 3. Chronology of Anticancer Drug Development -- 3.1 A historical background of cancer chemotherapy -- 3.2 Development of the anticancer drug screening systems -- 3.3 Chronology of the anticancer drug development -- 3.4 Clinical application of anticancer drugs -- 4. Alkylating Anticancer Drugs -- 4.1 Classical alkylating drugs -- 4.2 Nonclassical alkylating drugs -- 4.3 Alkylating-like agents: platinum compounds -- 5. Antimetabolic Anticancer Drugs -- 5.1 Folic acid derivatives -- 5.2 Purine analogs -- 5.3 Pyrimidine analogs -- 6. Natural Product Anticancer Drugs -- 6.1 Plant-derived anticancer drugs -- 6.2 Anticancer antibiotics -- 7. Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs -- 7.1 Immunotherapeutic anticancer drugs -- 7.2 Other miscellaneous anticancer drugs -- 8. Hormonal Anticancer Drugs -- 8.1 Hormonal anti-prostate-cancer drugs -- 8.2 Hormonal anti-breast-cancer drugs -- 8.3 Other hormonal anticancer drugs -- 9. Molecular Targeted Anticancer Drugs -- 9.1 Tretinoin (all-trans retinoic acid, ATRA) -- 9.2 Bcr-Abl Inhibitors -- 9.3 EGFR inhibitors -- 9.4 HER2 inhibitors -- 9.5 Angiogenesis inhibitors -- 9.6 Other kinase inhibitors -- 9.7 mTOR inhibitors -- 9.8 Other targeted anticancer antibody drugs -- 9.9 Epigenetic anticancer drugs -- 9.10 Proteasome inhibitors -- 9.11 Vismodegib: hedgehog pathway blocker -- 10. Complications of Anticancer Drugs and Their Management -- 10.1 Chemotherapy-induced nausea and vomiting (CINV) -- 10.2 Myelotoxicity (bone marrow toxicity) -- 10.3 Chemotherapy-induced diarrhea -- 10.4 Chemotherapy-induced constipation -- 10.5 Chemotherapy-induced urinary toxicity -- 10.6 Chemotherapy-induced pulmonary toxicity -- 10.7 Chemotherapy-induced neurotoxicity -- 10.8 Chemotherapy-induced neurotoxicity -- 10.9 Chemotherapy-induced oral mucositis -- 10.10 Anorexia -- 10.11 Tumor lysis syndrome -- 10.12 Extravasation of anticancer drugs -- 10.13 Chemotherapy-induced skin toxicity -- Part Ⅲ. A Paradigm Shift in Cancer Research -- 11. Advancements in Bioscience and New Cancer Drugs -- 11.1. Development of cancer drugs according to scientific advancements -- 11.2. New anticancer drugs.
520
$a
This book describes the history of cancer drugs development to provide insight into the successes and the shortcomings of this enterprise. Most cancer drug treatments target the cancer cell as the core component and as such are very effective in inhibiting their proliferation. However, these cancer drugs are generally ineffective against metastasis, which are tightly linked to the whole body as a system. This book illustrates the problems in cancer drug design and suggests a more systemic view of cancer with a more adapted research approach. The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs, which has been deeply influenced by the 'cell concept' of cancer. Future directions for the development of new anticancer drugs will also be presented. This book has been separated into three sections, providing an overview of: - The scientific progress in the biological sciences over the last 60 years and the influence this progress has had in cancer research. Summaries and charts of important discoveries complete this overview - The process of anticancer drug development with a focus on the characteristic drug groups of each era, illustrated by comprehensive timelines and conceptual cartoons - The limitations of the current cancer drug development pipelines and the new directions for cancer drug discovery, considering a more systemic view of cancer This book is a useful reference for scientists and clinicians working in the biomedical field and for oncologists aiming to explore the landscape of human endeavor in the fight against cancer.
650
0
$a
Antineoplastic agents
$x
Development.
$3
752563
650
0
$a
Cancer
$x
Chemotherapy.
$3
753516
650
1 4
$a
Biomedicine.
$3
890831
650
2 4
$a
Cancer Research.
$3
891172
650
2 4
$a
Pharmacy.
$3
636101
650
2 4
$a
History of Medicine.
$3
606308
700
1
$a
Kim, Kyu-Won.
$3
3200496
710
2
$a
SpringerLink (Online service)
$3
836513
773
0
$t
Springer eBooks
856
4 0
$u
http://dx.doi.org/10.1007/978-94-024-0844-7
950
$a
Biomedical and Life Sciences (Springer-11642)
筆 0 讀者評論
館藏地:
全部
電子資源
出版年:
卷號:
館藏
1 筆 • 頁數 1 •
1
條碼號
典藏地名稱
館藏流通類別
資料類型
索書號
使用類型
借閱狀態
預約狀態
備註欄
附件
W9312408
電子資源
11.線上閱覽_V
電子書
EB RS431.A64 C215 2016
一般使用(Normal)
在架
0
1 筆 • 頁數 1 •
1
多媒體
評論
新增評論
分享你的心得
Export
取書館
處理中
...
變更密碼
登入